Related Experiment Video
Updated: Mar 11, 2026
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
7.7K
Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debate?
1Prof. Erik Berntorp, Centre for Thrombosis and Hemostasis, Lund University, Skane University Hospital, Jan Waldenströms gata 14, SE-205 02, Malmö, Sweden, Tel: +46705752496,
Hamostaseologie
|November 24, 2016
Summary
Developing inhibitors is a major complication for hemophilia patients. Plasma-derived factor concentrates may offer protection against inhibitors in previously untreated patients, unlike recombinant products.
Area of Science:
- Hematology
- Immunology
- Biotechnology
Background:
- Inhibitor development is a significant complication in hemophilia treatment.
- Recombinant factor concentrates may increase inhibitor incidence in previously untreated patients (PUPs).
- Plasma-derived concentrates are suggested to have a protective role, potentially due to von Willebrand factor (VWF).
Purpose of the Study:
- To examine the role of different factor concentrate product classes in inhibitor development.
- To investigate the potential protective mechanisms of von Willebrand factor (VWF) in preventing inhibitor formation.
Main Methods:
- Review of cohort and surveillance studies on inhibitor development.
- Analysis of experimental data on VWF interaction with factor VIII and macrophages.
- Consideration of findings from the SIPPET randomized prospective study.
Main Results:
- Conflicting results exist regarding product class and inhibitor development.
- VWF may inhibit factor VIII uptake by macrophages, a potential mechanism for protection.
- The SIPPET study supported the notion that plasma-derived concentrates lead to fewer inhibitors in severe hemophilia A patients.
Conclusions:
- The role of product class in inhibitor development remains debated.
- Plasma-derived concentrates, potentially due to VWF content, may reduce inhibitor risk in previously untreated patients.
- Further research and discussion are warranted to clarify these findings.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
445
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
445
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
14.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
14.5K
01:24Disorders of Hemostasis
2.6K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.6K
01:16Clot Retraction and Fibrinolysis
9.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.8K